Valuation: Caplin Point Laboratories Limited

Market Cap 196B 2.05B 1.77B 1.68B 1.52B 2.85B 2.87B 20.02B 7.74B 99.61B 7.69B 7.52B 318B P/E 2027 *
27x
P/E 2028 * 23.3x
Enterprise Value 196B 2.05B 1.77B 1.68B 1.52B 2.85B 2.87B 20.02B 7.74B 99.61B 7.69B 7.52B 318B EV / Sales 2027 *
7.83x
EV / Sales 2028 * 6.93x
Free-Float
26.56%
Yield 2027 *
0.15%
Yield 2028 * 0.15%
1 day+0.99%
1 week-6.58%
Current month+3.66%
1 month+3.52%
3 months+11.83%
6 months+59.65%
Current year+41.72%
1 week 2,490.35
Extreme 2490.35
2,789
1 month 2,455
Extreme 2455
2,874
Current year 1,502.45
Extreme 1502.45
2,874
1 year 1,502.45
Extreme 1502.45
2,874
3 years 950
Extreme 950
2,874
5 years 575
Extreme 575
2,874
10 years 180
Extreme 180
2,874
Manager TitleAgeSince
Chief Executive Officer 71 27/03/2015
Director of Finance/CFO - 18/02/2016
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 26/01/2010
Director/Board Member - 04/11/2025
Director/Board Member 71 27/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%-6.58%+11.92%+150.48% 2.04B
-0.06%-0.44%+14.36%+61.45% 45.9B
+3.30%-1.70%+38.50%+102.33% 38.7B
+0.28%-0.65%+7.42%+72.60% 11.43B
-0.06%-1.08%-12.90%+9.50% 11.38B
+0.96%+0.57%+19.32%+148.82% 9.09B
-0.47%+0.16%+27.34%+36.96% 7.3B
+2.30%+1.66%+39.33%-18.59% 7.13B
-0.35%-0.41%+17.75%+182.43% 6.98B
+0.61%-5.43%-43.52%+5.23% 4.89B
Average +0.78%-1.92%+11.95%+75.12% 14.48B
Weighted average by Cap. +1.08%-2.55%+18.49%+74.67%

Financials

2027 *2028 *
Net sales 25.07B 261M 226M 214M 194M 364M 366M 2.56B 988M 12.72B 982M 960M 40.53B 28.34B 295M 256M 242M 220M 412M 414M 2.89B 1.12B 14.37B 1.11B 1.09B 45.82B
Net income 7.26B 75.73M 65.62M 62.03M 56.31M 106M 106M 740M 286M 3.68B 284M 278M 11.74B 8.41B 87.68M 75.98M 71.81M 65.2M 122M 123M 857M 331M 4.27B 329M 322M 13.6B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
4,199
Date Price Change Volume
17/09/26 2,611.50 +1.08% 1,008
16/09/26 ₹2,583.70 +0.50% 26,442
15/09/26 ₹2,570.80 -6.68% 9,379
11/09/26 ₹2,754.75 -1.37% 6,547
10/09/26 ₹2,793.00 +2.43% 20,070
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,583.70INR
Average target price
2,765.00INR
Spread / Average Target
+7.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPLIPOINT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!